Background
==========

Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing cognitive impairment in millions of elderly worldwide. Clinical practice today includes symptomatic treatment with stimulation therapy and/or pharmaceutical intervention with cholinesterase inhibitors (ChEI) due to lack of causal treatment \[[@B1],[@B2]\].

Non-pharmaceutical interventions on AD such as exercise training, occupational therapies and cognitive stimulation have been examined in studies of various design, size and duration. Until recently such interventions have not been tested in large-scale studies \[[@B3]\]. A Cochrane review (2003) described limited effects of cognitive stimulation therapy alone\[[@B4]\], but a meta-analysis including 30 trials studying the effect of exercise training in AD patients showed a significant effect on cognitive and functional performance as compared to the control group \[[@B5]\]. Graff and colleagues showed that occupational therapy improved cognitive function significantly and reduced the burden on caregivers \[[@B6]\]. Despite controversies, ChEIs have been promoted during the last fifteen years as symptomatic treatment of mild to moderate AD. Several meta-analyses have reported a modest effect of ChEI on cognition \[[@B7]-[@B9]\]. A head to head comparison of the effect of ChEI versus stimulation therapy has to our knowledge not been performed \[[@B3]\] although the combined effect of donepezil and stimulation therapy compared to control groups is examined in a few studies \[[@B10]-[@B12]\].

The main purpose of this study was to examine the effect of stimulation therapy on cognitive function in community dwellers with mild to moderate AD in Northern Norway. A secondary aim was to examine whether donepezil increased the effect of stimulation therapy on cognition.

Method
======

Design
------

The present study has a double design; - an open intervention with stimulation therapy to which a randomised double blinded and placebo-controlled clinical trial (RCT) with donepezil is added, constituting a two-by-two factorial design.

Participants
------------

General practitioners (GPs) recruited 87 and population-based screening 100 participants to the study, all with a recent diagnosis of AD at inclusion. 45 of these 187 participants (24%) were nursing home residents served by the primary health care in the participating municipalities and 142 lived in their own homes. 146 participants accomplished a one-year follow-up. At baseline no significant differences between subgroups were found with respect to age, gender, cognitive function, neuropsychiatric symptoms, activities of daily living, drug consumption, number of co-morbidities or education level (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}).

###### 

Baseline cognitive, neuropsychological and ADL function according to follow-up groups

  **Groups**            **n**   **MMSE ± SD\***   **ADAS-cog ± SD\***   **CDT\*\* ± SD\***   **BI§ ± SD\***   **NPI‡ ± SD\***
  --------------------- ------- ----------------- --------------------- -------------------- ---------------- -----------------
  Municipality                                                                                                 
  Stimulation           103     22.9 ± 4.6        18.9 ± 8.7            2.85 ± 1.2           6.08 ± 9·6       18.6 ± 2.6
  Standard care         77      23.5 ± 4.3        17.1 ± 7.0            2.84 ± 1.2           8.48 ± 10·5      18.6 ± 3.2
  p-value                       0.34              0.22                  0.96                 0.12             0.995
  Drug                                                                                                         
  Donepezil             90      23.2 ± 4.2        18.6 ± 7.7            2.86 ± 1.1           7.48 ± 11·4      18.9 ± 2.1
  Placebo               90      23.1 ± 4.8        17.9 ± 8.4            2.84 ± 1.2           6.70 ± 8·9       18.4 ± 3.4
  p-value                       0.83              0.55                  0.95                 0.61             0.29
  Combination                                                                                                  
  Donepezil             53      22.9 ± 4.5        19.2 ± 8.7            2.92 ± 1.1           6.29 ± 11·3      18.7 ± 2.3
  \+ stimulation                                                                                               
  Placebo                                                                                                      
  \+ Standard care      40      23.3 ± 4.9        17.2 ± 8.0            2.93 ± 1.2           7.76 ± 10·4      18.1 ± 4.0
  p-value                       0.64              0.24                  0.998                0.53             0.45
  Head to head                                                                                                 
  Stimulation therapy   50      22.9 ± 4.7        18.5 ± 8.7            2.78 ± 1.3           5.85 ± 7·4       18.6 ± 2.8
  Donepezil             37      23.7 ± 3.7        17.6 ± 5.8            2.76 ± 1.3           9.29 ± 10·8      19.1 ± 1.8
  p-value                       0.36              0.62                  0.93                 0.09             0.31

\*Mean values ± Standard deviation. \*\*CDT = Clock Drawing Test scale 0--4 (4 best function) §BI = Barthel Index, scale 0--20 (20 best function). ‡ NPI = Neuropsychiatric Inventory, Scale 0--144 (144 worst case).

###### 

Baseline demographic characteristics according to follow-up groups

  **Groups**                **Age ± SD\***   **Gender**   **Education**   **Living**                 
  ------------------------- ---------------- ------------ --------------- ------------ ------------ ------------
  Municipality                                                                                       
  Stimulation               81.6 ± 6.7       59(57)       88(85)          48(46)       1.82 ± 1.7   4.89 ± 3.3
  Standard care             4.89 ± 3.3       54(65)       65(79)          37(45)       1.65 ± 1.1   5.40 ± 3.9
  p-value                   0.12             0.25         0.34            0.83         0.45         0.34
  Drug                                                                                               
  Donepezil                 80.80 ± 6.8      62(67)       82(89)          39(42)       1.90 ± 1.7   5.10 ± 3.3
  Placebo                   80.85 ± 7.3      50(54)       70(75)          46(49)       1.59 ± 1.2   5.16 ± 3.8
  p-value                   0.96             0.07         0.014           0.30         0.15         0.90
  Combination                                                                                        
  Donepezil + stimulation   81.32 ± 7.0      31(60)       47(90)          28(54)       2.02 ± 2.0   4.92 ± 2.8
  Placebo + Standard care   79.81 ± 8.1      22(54)       29(71)          19(46)       1.51 ± 1.1   5.41 ± 3.9
  p-value                   0.34             0.57         0.015           0.47         0.14         0.48
  Head to head                                                                                       
  Stimulation therapy       81.89 ± 8.3      27(53)       40(78)          24(47)       1.61 ± 1.4   4.88 ± 3.7
  Donepezil                 80.17 ± 6.4      28(74)       32(86)          15(39)       1.76 ± 1.3   5.26 ± 4.0
  p-value                   0.21             0.046        0.33            0.45         0.61         0.65

\*Mean values ± standard deviation.

The recruitment methods and demographic characteristics are described in detail in a previous paper \[[@B13]\]. Inclusion criteria were individuals aged 65--100 years with a recent diagnosis of AD and Mini-Mental-State-Examination (MMSE) \[[@B14]\] sum score at least 10 points. A standard MMSE protocol translated into Norwegian was used and the protocol was not changed during the study period. At entry 43 participants tested between 10 and 20 MMSE points, 92 participants tested between 21 and 25 points and 52 participants tested 26 MMSE points or more.

Exclusion criteria were dementia other than AD, previous use of donepezil, behavioural disturbances making co-operation and cognitive testing impossible, inability to understand the purpose of the study, any expressed reluctance to participate, or relatives or caregivers disapproving participation. The study period lasted for 39 months of which 27 involved recruitment. All together 41 participants (22%) dropped out, seven prior to the first test and 34 between the first and the fourth (Figure [1](#F1){ref-type="fig"}).

![Flowchart of dropouts during follow-up.](1471-2377-12-59-1){#F1}

The study was community based and run on municipality level. Nine rural municipalities in Northern Norway with 70000 inhabitants were engaged. The age group ≥65 years in these communities constituted 11807 individuals. The municipalities were divided into two groups. Participants from five municipalities received stimulation therapy whereas the participants in the remaining four received standard care. The municipalities were selected to the study and allocated to stimulation therapy or standard care according to criteria such as number of inhabitants, age distribution and ethnical homogeneity. Professional competence level and a primary health care organized in accordance with the principles of good clinical practice in each participating municipality were required. Choosing maximum distance and pursuing the least contact possible between municipalities offering stimulation therapy or standard care intended to minimize the risk of dilution. These selection criteria were difficult to apply by random allocation, and each municipality was assigned to the intervention or control municipality group based on study staff consensus.

Randomisation and masking
-------------------------

The Clinical Research Centre at the University Hospital in Tromsø allocated all participants to donepezil or placebo (drug groups) in a randomised manner, in blocks of 4 to 6, by (Figure [2](#F2){ref-type="fig"}). The treatment assignments were blinded to all study personnel and participants.

![Flowchart of the study design and sample size divided on subgroups.](1471-2377-12-59-2){#F2}

Diagnosing Alzheimer's disease
------------------------------

A standardised testing program according to national guidelines was used. A semi-structured interview of the participants concentrating on the onset and the course of memory impairment, visuo-spatial disturbances, speech difficulties, executive dysfunctions, and problems with activities of daily living was performed. A family member or a caregiver completed or extended the medical history by adressing the Informant Questionnaire-Cognitive Decline in the Elderly (IQ-CODE) \[[@B15]\] which also assess social consequences of the cognitive impairment. Cognitive function was tested with MMSE and Clock Drawing Test (CDT) \[[@B16]\]. Depressive symptoms were assessed with a semi-structured questionnaire in addition to Montgomery and Aasberg Depression Rating Scale (MADRS) \[[@B17]\] testing AD participants with a MMSE sum score exceeding 21 points. A neurological examination, blood tests and cerebral computed tomography (CT) were performed. The diagnostic procedures for participants recruited by screening were similar to those used in general practice.

GPs and geriatric specialists diagnosed dementia and Alzheimer's disease according to the ICD-10 criteria \[[@B18]\] and the Statistical Manual of Mental Disorders fourth edition (DSM-IV-TR). Diagnostic discrepancies were discussed with a geriatric colleague both advised by National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer Disease and Related Disorders (NINCDS-ADRDA) criteria \[[@B19]\] for probable AD and solved by consensus. A third specialist (MV) was consulted if disagreement continued.

Outcome measures
----------------

The primary outcome was changes in MMSE sum score. In order to compare with other studies the cognitive tests were supplemented with Alzheimer's Disease Assessment Scale, Cognitive (ADAS-Cog) \[[@B20]\]. A change in ADAS-Cog and CDT were secondary outcomes. Basic activities of daily living were assessed with Barthel Index (BI) \[[@B21]\]. NeuroPsychiatric Inventory (NPI) \[[@B22]\] was used to identify psychiatric symptoms.

During one-year follow-up MMSE, CDT and ADAS-Cog were performed at baseline and at 4, 8 and 12 months, and all other tests at baseline and at 12 months. Two test technicians performed all testing after supervision and training at The Department of Geriatrics, University Hospital in Northern Norway. To improve intra and inter-rater reliability they observed and evaluated each other by testing a number of patients with MMSE, ADAS-Cog and NPI prior to the study onset.

Intervention
------------

### Stimulation therapy

A program of stimulation therapy including physical activities, cognitive, sensory and social stimulation was developed and adjusted to each participant taking cognitive and physical function, educational level and professional background into consideration. The program included systematically performed and intensified daily activities like walking, domestic work, regular reading of books and papers, training in fitness rooms, dancing, crossword puzzles, listening to music, and regular participation in the social life of the community. A few more sophisticated activities such as reminiscence groups, Sudoku, aroma therapy and sensory garden were added, between which the participants could move freely. This stimulation therapy was carried out for a minimum of 30 minutes 5 days a week for one year (maximum 250 sessions a year) in close co-operation with the participant and his/her family or trained health providers. Each session of stimulation therapy was described in a log which was submitted to the study site weekly. These were then compared to the pre-plan individual stimulation program and assessed consecutively, approved or rejected by the study staff. In nursing homes the employee conducted the stimulation therapy while community nurses or other caregivers (family members or even neighbors) guided by the nurses were responsible for the stimulation therapy of community dwellers not regularly receiving community health care. The stimulation program was monitored and adjusted according to functional abilities and interests of the participants during the period of intervention. Nursing home residents and community dwellers received the same stimulation program with an exception for the individual adjustment. Participants living in municipalities allocated to standard care did not receive any organized stimulation.

### Drug

Having received the randomization codes the pharmacy at the hospital in Bodø distributed the drugs to the patient or the caregiver according to a prescription from the family physician. All participants were prescribed donepezil or placebo once daily. Passing four weeks the dosage was increased from 5 to 10 mg. Adverse events were recorded consecutively.

Ethics and approvals
--------------------

The present study was approved by the national authorities including The Regional Committee for Medical Research Ethics in Northern Norway, The Privacy Ombudsman for Research, The Directory of Health and Social Welfare and The Norwegian Medicine Agency with registration in the EudraCT database (no 2004-002613-37). Each participant gave a written informed consent co-signed by a spouse, a close relative or a guardian. The national authorities listed above approved the consent formula and the study was registered as an International Standard Randomized Controlled Trial within ClinicalTrials.gov (Identifier: NCT00443014). In October 2008 The Norwegian Medicine Agency conducted an inspection according to the principles of Good Clinical Practice in a randomized clinical trial. All remarks from this assessment, including monitoring routines were closed and approved.

All the publications from this study comply with The CONSORT statements 2010 and the updated Uniform Requirements for Manuscripts Submitted to Biomedical Journals.

Statistics
----------

Statistical analyses were carried out using SPSS version 15.0 and 18 (SPSS Inc. Chicago, US). Differences in demographic characteristics between municipality and medicine groups were assessed by independent sample t-tests or Chi-square. Repeated measures analyses assessed differences in time-trends between groups of participants completing one-year follow-up. Linear mixed models were used to assess time-trends in cognitive function over four time points and to assess differences in time-trends between groups of participants with and without baseline cognitive function as covariate. Including an unstructured covariance matrix to the model controlled for possible dependences between repeated observations. In the municipality groups, time trend differences in cognitive function were assessed between the stimulation group and controls, and differences in the medicine groups were assessed between donepezil treatment group and placebo. Finally, the subgroup treated by stimulation therapy and donepezil was compared to the subgroup receiving usual care and placebo. Model assumptions were assessed by means of residual analyses. The statistical analyses were performed according to intention to treat, per protocol and subgroup analyses in order to estimate homogeneity and consistency of the data. In sensitivity analyses we included municipality as random effect in the linear mixed models in order to control for possible clustering of data within the municipalities.

Results
=======

No significant time trend differences in cognitive performance were observed between participants receiving stimulation therapy or standard care during one year, assessed by MMSE (primary outcome), CDT and ADAS-Cog (secondary outcome). The cognitive test performances remained unchanged during the study period, and addition of donepezil or placebo to the study groups did not alter the results (Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}). Repeated measures analyses were consistent with the linear mixed model analyses (Data not shown).

###### 

Mean cognitive function in the municipality and drug groups by follow-up time point. Intention to treat analyses

           **Groups**            **Moments of follow-up**                                                
  ----------------------------- -------------------------- ------------ ------------ ------------ ------ -------
          MMSE ± SD\*\*                                                                                  
          Municipality                                                                                   
      Stimulation (n = 103)             22.9 ± 4.6         22.1 ± 5.0   22.9 ± 4.5   22.6 ± 5.2   0.15   0.017
     Standard care (n = 77)             23.5 ± 4.3         23.8 ± 4.    24.4 ± 4.0   23.9 ± 4.3           
              Drug                                                                                       
       Donepezil (n = 90)               23.2 ± 4.2         23.3 ± 4.5   23.8 ± 4.3   23.0 ± 4.9   0.31   0.21
         Placebo n = 90                 23.1 ± 4.1         22.9 ± 4.8   23.4 ± 4.3   23.3 ± 4.8           
   Clock Drawing Test ± SD\*\*                                                                           
          Municipality                                                                                   
           Stimulation                  2.9 ± 1.2          2.9 ± 1.1    2.8 ± 1.1    3.0 ± 1.1    0.21   0.071
          Standard care                 2.8 ± 1.2          3.0 ± 1.2    3.1 ± 1.1    3.1 ± 1.1            
              Drug                                                                                        
            Donepezil                   2.9 ± 1.2          2.8 ± 1.2    2.8 ± 1.2    3.0 ± 1.0    0.56   0.26
             Placebo                    2.8 ± 1.1          3.0 ± 1.1    3.0 ± 1.0    3.1 ± 1.1            
        ADAS-cog ± SD\*\*                                                                                
          Municipality                                                                                   
           Stimulation                  18.9 ± 8.7         18.5 ± 8.4   17.0 ± 9.1   16.8 ± 8.5   0.23   0.11
          Standard care                 17.4 ± 7.0         16.1 ± 6.9   15.7 ± 8.2   15.9 ± 8.0           
              Drug                                                                                       
            Donepezil                   18.6 ± 7.6         17.7 ± 7.8   16.3 ± 8.8   16.3 ± 8.4   0.59   0.24
             Placebo                    17.9 ± 8.4         17.1 ± 7.9   16.5 ± 8.6   16.4 ± 8.2           

\*n varies due to dropouts during follow-up. \*\* Standard deviation. p-value^1^ = Equal time trends between groups. p-value^2^ = Equal time trend between groups adjusted for baseline cognitive function.

###### 

Estimated change in cognitive function by follow-up time point and according to drug groups and municipality groups\*

                        **Estimated change (95% CI) versus baseline at**   **p-values**                                                
  --------------------- -------------------------------------------------- ------------------------- ------------------------- ------- -------
  MMSE                                                                                                                                 
  Drug groups                                                                                                                           
  Placebo               −0.402 (−0.988, 0.185)                             −0.015 (−0.584, 0.553)    −0.335 (−1.046, 0.375)    0.208   0.284
  Donepezil             0.145 (−0.440, 0.730)                              0.411 (−0.166, 0.988)     −0.470 (−1.181, 0.241)             
  Municipality groups                                                                                                                   
  Standard care         0.198 (−0.429, 0.826)                              0.790 ( 0.190, 1.389)     0.156 (−0.588, 0.901)     0.017   0.508
  Stimulation           −0.380 (−0.933, 0.172)                             −0.272 (−0.807, 0.262)    −0.841 (−1.510, -0.172)            
  Clock Drawing Test                                                                                                                   
  Drug groups                                                                                                                           
  Placebo               0.103 (−0.081, 0.288)                              0.124 (−0.082, 0.330)     0.134 (−0.079, 0.347)     0.264   0.570
  Donepezil             −0.016 (−0.200, 0.169)                             −0.101 (−0.309, 0.107)    0.031 (−0.183, 0.245)              
  Municipality groups                                                                                                                   
  Standard care         0.120 (−0.076, 0.317)                              0.210 (−0.008, 0.428)     0.234 ( 0.011, 0.456)     0.071   0.257
  Stimulation           −0.017 (−0.191, 0.158)                             −0.144 (−0.339, 0.050)    −0.038 (−0.242, 0.165)             
  ADAS-cog                                                                                                                             
  Drug groups                                                                                                                           
  Placebo               −0.383 (−1.412, 0.646)                             −1.126 (−2.201, -0.051)   −0.492 (−1.635, 0.650)    0.235   0.886
  Donepezil             −1.027 (−2.053, -0.001)                            −1.948 (−3.033, -0.862)   −1.510 (−2.661, -0.359)            
  Municipality groups                                                                                                                   
  Standard care         −1.515 (−2.597, -0.433)                            −1.736 (−2.889, -0.582)   −1.619 (−2.830, -0.407)   0.108   0.242
  Stimulation           −0.069 (−1.030, 0.893)                             −1.380 (−2.407, -0.352)   −0.493 (−1.590, 0.603)             

\* Linear mixed models adjusted for baseline cognitive score.

P^1^, p-value for overall equality of change between the groups.

P^2^, p-value for test of interaction between group and time, i.e. test for constant differences between groups over time.

When comparing stimulation therapy and donepezil head to head, time-trend analysis showed non-significant changes for CDT and ADAS-Cog, whereas the MMSE test showed borderline significance (p = 0.042) (Table [5](#T5){ref-type="table"}). A subgroup analysis comparing the extremes, the combined effect of stimulation therapy and donepezil versus standard care and placebo, did not reveal any significant time-trend differences in cognitive performance (Table [6](#T6){ref-type="table"}). Including municipality as a random factor did not change the main result of the study (data not shown).

###### 

Mean cognitive function by follow-up time point and according to a head to head comparison between donepezil versus stimulation therapy

  **Groups**            **Time points**               **p-value**^**1**^   **p-value**^**2**^                        
  --------------------- ----------------------------- -------------------- -------------------- ------------ ------- --------
                        MMSE ± SD\*\*                                                                                
  Stimulation therapy   22.9 ± 4.5                    22.2 ± 5.1           23.0 ± 4.0           22.7 ± 4.8   0.040   0.0016
  Donepezil             23.7 ± 3.7                    23.8 ± 3.8           25.1 ± 3.0           23.6 ± 3.8            
                        Clock Drawing Test ± SD\*\*                                                                  
  Stimulation therapy   2.8 ± 1.3                     2.9 ± 1.2            2.8 ± 1.0            2.9 ± 1.1    0.940   0.713
  Donepezil             2.8 ± 1.3                     2.7 ± 1.3            2.8 ± 1.2            2.9 ± 1.1             
                        ADAS-cog ± SD\*\*                                                                            
  Stimulation therapy   18.5 ± 8.7                    17.9 ± 8.6           16.7 ± 8.8           17.6 ± 8.6   0.225   0.060
  Donepezil             17.6 ± 5.8                    15.8 ± 6.9           15.1 ± 7.9           16.7 ± 8.1            

n varies due to missing values \*\* Standard deviation. p-value^1^ = Equal time trends between groups. p-value^2^ = Equal time trend between groups adjusted for baseline cognitive function.

###### 

Mean cognitive function by follow-up time point and according to donepezil added to stimulation therapy versus placebo added to standard care

             **Groups**             **Time points**                                                  
  --------------------------------- ----------------- ------------ ------------ ------------ ------- -------
            MMSE ± SD\*\*                                                                            
   Donepezil + stimulation therapy  22.9 ± 4.5        22.9 ± 4.5   22.9 ± 4.9   22.5 ± 5.5   0.443   0.449
       Placebo + standard care      23.3 ± 4.9        23.8 ± 4.2   23.6 ± 4.6   24.1 ± 4.7            
     Clock Drawing Test ± SD\*\*                                                                     
   Donepezil + stimulation therapy  2.9 ± 1.1         2.9 ± 1.1    2.8 ± 1.2    3.1 ± 1.0    0.064   0.035
       Placebo + standard care      2.9 ± 1.2         3.2 ± 1.0    3.3 ± 1.0    3.3 ± 1.1             
          ADAS-cog ± SD\*\*                                                                          
   Donepezil + stimulation therapy  19.3 ± 8.7        19.2 ± 8.2   17.2 ± 9.5   16.1 ± 8.7   0.554   0.458
       Placebo + standard care      17.2 ± 8.0        16.3 ± 7.1   16.3 ± 8.5   15.1 ± 7.9            

\* n varies due to missing values \*\* Standard deviation. p-value^1^ = Equal time trends between groups. p-value^2^ = Equal time trend between groups adjusted for baseline cognitive function.

Baseline demographic characteristics were well balanced between compared groups with respect to, cognitive performance, activities of daily living (ADL), neuropsychiatric symptoms (NPI) (Table [1](#T1){ref-type="table"}), age, gender, social living, drug consumption and co-morbidities (Table [2](#T2){ref-type="table"}). The educational level was significantly lower in the donepezil group compared to placebo (Table [2](#T2){ref-type="table"}). Of 187 study participants, 146 completed one year follow-up, and 41 withdrew due to disease progression (n = 8), co-morbidity (n = 8), death (n = 7), or unknown reason (n = 18) (Figure [1](#F1){ref-type="fig"}). The dropouts were equally distributed between subgroups. At entry the dropouts were older (82.5 ± 7.1 versus 80.4 ± 6.9 years), and more cognitively impaired (MMSE 21.17 ± 4.1 versus 23.48 ± 3.7) compared to those completing the study period.

22 participants (25%) dropped out from the donepezil group due to adverse reactions compared to 8 (10%) in the placebo group, p = 0.008 (data not shown). 17 participants in the donepezil group reported gastrointestinal reactions, especially anorexia, diarrhoea and nausea compared to 6 in the placebo group. Participants using donepezil reported depression, dizziness, nightmare and headache whereas these symptoms were uncommon in the placebo group. In two cases the adverse reactions were temporarily and the medication could be resumed. In the other cases the symptoms remained and the drug treatment had to be interrupted.

Discussion
==========

In this one-year trial, there were no significant changes in cognitive performance between AD participants receiving stimulation therapy or standard care. To our surprise, both groups retained their cognitive function and the results were consistent for three different cognitive tests as assessed at quarterly sessions during the study period. Among the participants receiving standard care, we expected an annual decline of 2--3 MMSE points, or an increase of 5--12 ADAS-Cog points, which is the natural course of AD \[[@B23],[@B24]\].

Our results are in agreement with others \[[@B25],[@B26]\] who reported small changes in mean MMSE score in controls receiving standard care. This is in contrast with Requena et al \[[@B10]\], who reported a significant decline in mean MMSE score from 19.4 (SD 4.9) to 13.1 (SD 5.9) after one year without intervention, but an increase in mean MMSE score from 19.4 (SD 8.2) to 21.9 (SD 7.9) after one year for AD subjects receiving stimulation therapy. However, these studies are limited by short follow up \[[@B25]\], retrospective design, poorly defined controls \[[@B26]\], small sample size and an open design \[[@B10]\].

In our study, there were no differences in cognitive performance between the groups given donepezil or placebo, irrespective of stimulation therapy or standard care. Chapman et al \[[@B12]\] and Matsuda et al \[[@B11]\] reported non-significant changes in mean MMSE score in the combined treatment group given donepezil and stimulation therapy after one year (−1.3 and +0.3 respectively), but a significant reduction in cognitive performance was observed in the donepezil only group (−2.9 and −2.0 respectively). Requena et al reported improved mean MMSE score (+1.5 points) after one year and a minimal reduction after two years in the combined treatment group (−1.3 points), whereas AD participants receiving donepezil without specific stimulation and AD participants in the control group had significantly lower MMSE score (−3.4 and −6.3, respectively). Our results partially support these studies \[[@B10]-[@B12]\] as the effect of stimulation on cognitive performance, with or without donepezil, did not deteriorate after one year. However, unlike Requena et al, our participants receiving donepezil or placebo added to standard care retained cognitive performance after one year. The differences could be due to smaller sample size and greater variation in cognitive function among participants in the Requena et al study compared to the present study. Differences in baseline cognitive function between mild and moderate AD may also give different cognitive deterioration slopes.

In a recent systematic review, Olazarán et al \[[@B27]\] has evaluated best effect of nonpharmacological therapies. Evidence of potential grade A treatment recommendation was reported for the effect of multicomponent intervention in delaying institutionalisation and grade B treatment recommendation for improvement in cognition and of activity of daily living. The intervention program of the present study is in accordance with these recommendations.

Several events and mechanisms may explain the similar cognitive performances between participants receiving stimulation therapy and standard care. In our study all groups were engaged in some treatment regimen also the standard care group that received placebo. We suggest that even this group was exposed to more than standard care throughout the study period because of overly enthusiastic co-workers including test technicians who became involved in activities that exceeded their predefined roles. Frequent monitoring and follow-ups do increase the attention given to the patients by family members, caregivers and study staff. This may act as stimulation in itself and generate an expectancy of a beneficial outcome \[[@B28]\]. We know from the experiences of industrial companies that production may increase no matter what changes are introduced to the workers or working conditions, "the Hawthorne effect" \[[@B29]\]. The Hawthorn effect has to our knowledge only been addressed in one single AD study \[[@B30]\]. This effect is not sufficiently described in clinical AD trials \[[@B31],[@B32]\], and it may contribute to controls performing better than expected.

Beside the above-mentioned mechanisms, our study results may have been affected by a national AD campaign launched at the same time. That campaign focus on the beneficial effects of cognitive stimulation. This could have contributed to a diffusion of the therapeutic procedures across municipality borders and diluted the differences between stimulation therapy and standard care.

Strengths and weaknesses
------------------------

Our study is population-based with few exclusion criteria. This is different from several other studies which recruited AD individuals from hospitals, memory clinics or nursing homes using restrictive inclusion and wide exclusion criteria that could influence study samples and results. Our study population is ethnically and socially homogenous, and the baseline characteristics did not differ between defined strata. The two-by-two factorial design in our study enables a head to head comparison between stimulation therapy and drug treatment

Participants remained in their own environment during the entire study period. None of the participants used memantin or other ChEI. Although 23% of the participants used anticholinergic drugs for co-morbidities \[[@B33]\], inappropriate drugs were equally distributed between groups and could hardly explain the results.Our participants received structured stimulation therapy on a daily basis and had few dropouts (22%), and the dropouts were equally distributed among subgroups. A possible weakness is that lower MMSE score among dropouts could have influenced mean cognitive deterioration during follow-up. However, repeated measure analyses confirmed the main result of the study.

Another possible weakness is that despite randomisation, participants in the donepezil group had a lower educational level compared to the placebo group. Less education is associated with an increased risk of AD \[[@B2]\] but it is questionable whether this risk factor has an influence on the cognitive trajectory in AD in any way. The non-randomized allocation of the participating municipalities to stimulation therapy or standard care could be considered a weakness. However, a sensitivity analysis done to control for possible clustering of data within the municipalities did not change the results. The ability of the applied tests to detect a change in cognitive performance is questioned in early stage AD \[[@B18]\]. However, a stratified analysis of a subgroup presenting a MMSE score less than 21 points at entry (n = 43) showed no differences, and the results were consistent for all three cognitive tests (data not shown). It is therefore unlikely that a MMSE learning effect has occurred.

Furthermore, the stratified samples in the two-by-two factorial analysis that we did could be prone to type II errors due to relatively small sample sizes - especially the subgroup analyses of participants with MMSE \< 21. However, the differences between all groups were consistent for all three tests. Another consequence of the two-by-two factorial design was that no subgroup was left without any intervention. Even the standard care group received either placebo or donepezil. This could have increased the expectancy of a favourable outcome in the control groups and diluted the results \[[@B28]\].

Conclusion
==========

Participants with recently diagnosed AD receiving stimulation therapy retained cognitive function during the one-year follow-up as did also AD participants receiving standard care. Donepezil therapy had no additional effect on cognition. Our results need to be confirmed in future studies.
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